Subjects who are planning any fertility treatment within 6 months of study participation
Use of weight loss agents, including herbal medications, in the past 3 months
Current or anticipated chronic use of narcotics or opiates
History of severe psychiatric disorders
Type 1 diabetes mellitus
Metabolic disorders or genetic disorders linked to obesity
History of any bariatric surgery
Participation in any clinical study with an investigational drug or device within the 3 months prior to enrollment in this study
Blood loss or donation \>500 mL within the past 3 months
Females who are pregnant, nursing, intend to become pregnant during the study or any males who plan to father/conceive a child within 6 months after completion of study participation
Clareo Health | An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
